Department of Pathology, Shandong University School of Medicine, 44#, Wenhua Xi Road, Jinan, Shandong 250012, People's Republic of China.
Diagn Pathol. 2013 Aug 2;8:129. doi: 10.1186/1746-1596-8-129.
Coactivator-associated arginine methyltransferase 1 (CARM1) belongs to the protein arginine methyltransferase family. CARM1 has been reported to be associated with high grade tumors in breast cancer. It still remains unknown the expression pattern of CARM1 in breast cancer and its relationships with clinicopathological characteristics and molecular subtypes.
Two hundred forty-seven invasive breast cancer cases were collected and prepared for tissue array. There were thirty-seven tumors with benign glandular epithelium adjacent to the tumors among these cases. Molecular subtype and CARM1 expression were investigated using immunohistochemistry.
Cell staining was observed in the cytoplasm and/or nucleus. Staining for CARM1 was significantly stronger in adenocarcinoma compared with adjacent benign epithelium. There is a significant correlation between CARM1 overexpression with young age, high grade, estrogen receptor (ER) and progesterone receptor (PR) negative, increased p53 expression, and high Ki-67 index. Our study demonstrated CARM1 overexpression was associated with an increase in the protein expression of HER2. Furthermore, our data indicated CARM1-overexpression rate were remarkably higher in HER2 subtype (69.6%), luminal B subtype (59.6%) and TN subtype (57.1%) compared with luminal A subtype (41.3%).
CARM1 expression was increased in invasive breast cancer. CARM1 overexpression was associated with poorly characterized clinicopathologic parameters and HER2 overexpression. There were significant differences between different molecular subtypes in their relationship to CARM1 overexpression. Our results support the value of using CARM1 in prognostic stratification of breast cancer patients and its potential therapeutic implications in targeting treatment.
The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/4116338491022965.
共激活因子相关精氨酸甲基转移酶 1（CARM1）属于蛋白质精氨酸甲基转移酶家族。已有报道称，CARM1 与乳腺癌中的高级别肿瘤有关。CARM1 在乳腺癌中的表达模式及其与临床病理特征和分子亚型的关系尚不清楚。
收集了 247 例浸润性乳腺癌病例，并制备组织阵列。这些病例中有 37 例肿瘤旁有良性腺上皮。采用免疫组织化学法检测分子亚型和 CARM1 表达。
细胞质和/或细胞核观察到细胞染色。与相邻良性上皮相比，腺癌中 CARM1 的染色明显更强。CARM1 过表达与年轻、高级别、雌激素受体（ER）和孕激素受体（PR）阴性、p53 表达增加以及 Ki-67 指数高有关。本研究表明，CARM1 过表达与 HER2 蛋白表达增加有关。此外，我们的数据表明，在 HER2 亚型（69.6%）、管腔 B 亚型（59.6%）和 TN 亚型（57.1%）中，CARM1 过表达率明显高于管腔 A 亚型（41.3%）。
CARM1 在浸润性乳腺癌中表达增加。CARM1 过表达与特征不良的临床病理参数和 HER2 过表达有关。不同分子亚型在与 CARM1 过表达的关系上存在显著差异。我们的研究结果支持在乳腺癌患者的预后分层中使用 CARM1 的价值及其在靶向治疗中的潜在治疗意义。
本文的虚拟幻灯片可以在这里找到：http://www.diagnosticpathology.diagnomx.eu/vs/4116338491022965.
